CRISPR/Cas9 Mediated Disruption of the Swedish APP Allele as a Therapeutic Approach for Early-Onset Alzheimer’s Disease
Bence György(University of Basel), Martin Ingelsson(Uppsala University), Lars Lannfelt(BioArctic Neuroscience (Sweden)), Vilmantas Giedraitis(Uppsala University), Dakai Mu(Harvard University), Mikołaj Piotr Zaborowski(Poznan University of Medical Sciences), Benjamin P. Kleinstiver(Harvard University), J. Keith Joung(Massachusetts General Hospital), Ksenia V. Kastanenka(Harvard University), Casey A. Maguire(Harvard University), Bradley T. Hyman(Harvard University), Adrienn Volak(Massachusetts General Hospital), Camilla Lööv(Uppsala University), Caitlin Commins(Harvard University), Xandra O. Breakefield(Harvard University), Shuko Takeda(Osaka Gakuin University)
Cited by 189
Related Papers
The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
|Alzheimer s & Dementia|2011|18.9k
An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest
|NeuroImage|2006|14.1k
High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells
|Nature Biotechnology|2013|3.3k
National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease
|Alzheimer s & Dementia|2012|3.2k
CRISPR-Cas systems for editing, regulating and targeting genomes
|Nature Biotechnology|2014|3.2k